Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by Tempest Therapeutics, Inc. on June 15, 2023. The filing details the election of directors, the approval of an amended equity incentive plan, executive compensation advisory votes, and the ratification of the independent auditor.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Revenue, profit, cash flow, margins, debt, and liquidity metrics are not provided in this document.
Material Changes and Voting Results
As of the record date (April 18, 2023), 10,561,700 shares were outstanding. Approximately 84.28% of shares were present at the meeting. Key outcomes include:
- Equity Plan Approval: Stockholders approved the Amended and Restated 2023 Equity Incentive Plan (2023 EIP), replacing the 2019 plan. This increases shares available for issuance by 1,150,000, extends the annual share refresh period through 2033, and sets a 10,000,000 share cap for Incentive Stock Options (ISOs).
- Director Elections: Thomas Dubensky and Christine Pellizzari were elected as Class II directors to serve until the 2026 Annual Meeting.
- Executive Compensation: Stockholders approved the advisory vote on named executive officer compensation.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors. The document references the definitive proxy statement filed on May 1, 2023, for a complete summary of the 2023 EIP terms.
Investor Verification Checklist
- Verify the total number of shares authorized under the new 2023 EIP and the impact of the 1,150,000 share increase on potential dilution.
- Review the full text of the 2023 EIP in Appendix A of the May 1, 2023 Proxy Statement for specific vesting and exercise terms.
- Confirm the tenure of the newly elected Class II directors (Thomas Dubensky and Christine Pellizzari) through 2026.
- Check subsequent filings for the company's financial performance, as this 8-K contains no revenue or cash flow data.